Example collocations logo

Pharmaceutical in sentence

484 examples of Pharmaceutical in a sentence

Inward FDI could increase by as much as 83% annually by 2020; in the pharmaceutical industry alone, FDI could reach as much as $77 billion, with R&D rising to $4.2 billion and 44,000 new jobs being created.
The Indian government’s ongoing assault on pharmaceutical IP makes these findings even more significant.
As a chorus of researchers has pointed out, the provisions, pushed by the pharmaceutical companies, were so unbalanced that they were bad for scientific progress.
They could, for example, try to persuade the US to stop selling arms to Pakistan, or secure better access to the American market for India’s highly competitive IT and pharmaceutical sectors, which are facing new US non-tariff barriers.
Tracking Big Pharma’s Progress on AMRLONDON – This week, at the World Economic Forum’s annual meeting in Davos, the Access to Medicine Foundation (AMF) is launching an antimicrobial resistance (AMR) benchmark to “track how pharmaceutical companies are responding to the increase in drug-resistance.”
For the past ten years, the AMF, which is independent of the pharmaceutical industry, has published a highly regarded Access to Medicine Index, making it uniquely suited to quantify how various companies measure up in the fight against AMR.
During our Review, I learned that many in the investment community were not interested in pharmaceutical companies’ behavior on this issue, because there were no readily available data by which to make comparisons.
For its part, the AFM will calculate its benchmark separately for the eight major pharmaceutical companies that currently appear to be working on replacement drugs, generic producers, and firms focused solely on research and development.
We determined that an effective market-entry reward could be funded by small levies on the sales of the other top-50 pharmaceutical firms that are not carrying their weight.
But for now, let us hope the pharmaceutical benchmark gets the attention it deserves.
One common argument is that governments should protect biodiversity because of its untapped potential for the pharmaceutical industry.
Thus, the potential for pharmaceutical development will not provide strong encouragement to private landowners or companies to protect their land.
Sudan bore the brunt of US retaliation, when President Bill Clinton ordered the bombing of an apparently harmless pharmaceutical factory near Khartoum as retaliation for an Osama bin Laden sponsored terrorist attack.
A few major pharmaceutical companies compete for a finite group of diabetics by offering new formulations, marginal improvements in blood-sugar control, competitive pricing, and strategic partnerships with insurers and health-care providers.
In China, for example, the manufacturers of pharmaceutical ingredients can dodge drug regulation by claiming that their products will be used for non-medical purposes.
Governments must double or even triple investment in energy R&D, while ensuring that energy start-ups have the same access to finance as, say, telecommunications or pharmaceutical companies.
When the Japanese company Daiichi Sankyo paid $4.6 billion for majority control of the Ranbury pharmaceutical group in 2008, they were placing a bet on continuing corporate success.
By this narrow logic, when it comes to the pharmaceutical industry, we should be unconcerned if drug firms’ share prices are boosted not by new discoveries, but by financial maneuvers, such as share buybacks or tax inversion.
But the pharmaceutical industry is not an industry like any other.
The pharmaceutical industry is at its best when private profitability and social good coincide, as it does when useful new drugs attract large market shares.
But much of the pharmaceutical industry has abandoned this pursuit.
In January, the pharmaceutical industry took a big step toward solving this problem when more than 100 companies and trade associations from more than 20 countries signed a declaration calling on governments to adopt a new model of antibiotic development.
One option would be a small access-to-market fee that could be collected by pharmaceutical regulators in large markets.
This system recognizes that antibiotics are a shared and exhaustible resource on which the viability of a range of other pharmaceutical products and medical devices – from chemotherapy to joint replacements – depends.
The necessary $2.5 billion per year would amount to just 0.25% of global pharmaceutical sales – hardly a strain on an industry that is, by and large, in sound financial health.
National efforts are also strengthening pharmaceutical supply chains, improving medical training, and increasing the quality of diagnostic networks.
We have teamed up with the American Cancer Society (ACS) and the pharmaceutical company Novartis to support cancer treatment and testing efforts in four countries: Ethiopia, Rwanda, Tanzania, and Uganda.
With new patent laws coming into place, India will have the same attraction for the pharmaceutical industry as it has for IT, providing clinical trials for new drugs at a quarter of the cost of Europe or the US.
During my time as the head of the British government’s Review on Antimicrobial Resistance, I had to develop a better understanding of the pharmaceutical industry, and I learned that there is something to be said for microeconomic forces – and for basic common sense.
Daniel Vasella, the chairman and CEO of Switzerland-based Novartis, the world's fifth largest pharmaceutical company, recently wrote that multinational companies "have a duty to adhere to fundamental values and to support and promote them."
BackNext